ClinConnect ClinConnect Logo
Search / Trial NCT06541002

A Novel Digital Application (SHIFT) to Improve Outcomes for Hematopoietic Stem Cell Transplant Survivors

Launched by MASSACHUSETTS GENERAL HOSPITAL · Aug 2, 2024

Trial Information

Current as of June 26, 2025

Recruiting

Keywords

ClinConnect Summary

This clinical trial, called SHIFT, is looking at a new digital app designed to help people who have undergone hematopoietic stem cell transplants (HCT) improve their sexual health and overall quality of life. The study aims to support survivors dealing with sexual dysfunction and emotional distress after their treatment. The trial is not yet recruiting participants, but it will include adults aged 18 and older who had a stem cell transplant at least three months ago and are experiencing sexual health issues that are causing them distress.

To join the study, participants will need to answer some screening questions to confirm their eligibility. It's important to note that the app will only be available in English and Spanish, so participants should be comfortable with either of these languages. Additionally, individuals with certain major mental health conditions that might affect their ability to participate will not be eligible. If you qualify and decide to take part, you can expect to use the app on your own, which is designed to help improve your sexual health and well-being after your transplant.

Gender

ALL

Eligibility criteria

  • Inclusion Criteria:
  • Adult patients (\> 18 years) who underwent autologous or allogeneic HCT \> three months prior to study enrollment
  • Screen positive for sexual health concerns causing distress based on the National Comprehensive Network (NCCN) survivorship guidelines screening questions
  • Exclusion Criteria:
  • Patients who do not comprehend English or Spanish since SHIFT will only be available in these two languages for this efficacy trial.
  • Patients with any major uncontrolled psychiatric disorder or other comorbid cognitive conditions, which the treating HCT clinician believes would prohibit the patients' capacity to provide informed consent and participate in study procedures.

About Massachusetts General Hospital

Massachusetts General Hospital (MGH) is a leading academic medical center located in Boston, Massachusetts, renowned for its commitment to advancing medical research and patient care. As a prominent teaching hospital affiliated with Harvard Medical School, MGH plays a pivotal role in clinical trials across a wide range of disciplines, including cardiology, oncology, neurology, and more. The institution is dedicated to fostering innovative research that translates into effective therapies and improved health outcomes. MGH's Clinical Trials Office provides comprehensive support to facilitate the design, implementation, and management of clinical studies, ensuring adherence to the highest ethical standards and regulatory compliance. With a focus on collaboration and patient-centered care, MGH strives to enhance medical knowledge and contribute to the future of healthcare.

Locations

Philadelphia, Pennsylvania, United States

Boston, Massachusetts, United States

Coral Gables, Florida, United States

Patients applied

0 patients applied

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported